J
Jorge M. Chaves
Publications - 9
Citations - 902
Jorge M. Chaves is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 4, co-authored 4 publications receiving 711 citations.
Papers
More filters
Journal ArticleDOI
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd,Bonnie K. Harrington,Susan O'Brien,Jeffrey A. Jones,Anna Schuh,S Devereux,Jorge M. Chaves,William G. Wierda,Farrukh T. Awan,Jennifer R. Brown,Peter Hillmen,Deborah M. Stephens,Paolo Ghia,Jacqueline C. Barrientos,John M. Pagel,Jennifer A. Woyach,Dave Johnson,Jane Huang,Xiaolin Wang,Allard Kaptein,Brian J. Lannutti,Todd Covey,Maria Fardis,Jesse McGreivy,Ahmed Hamdy,Wayne Rothbaum,Raquel Izumi,Thomas G. Diacovo,Amy J. Johnson,Richard R. Furman +29 more
TL;DR: In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion.
Journal ArticleDOI
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
John C. Byrd,William G. Wierda,Anna Schuh,Stephen Devereux,Jorge M. Chaves,Jennifer R. Brown,Peter Hillmen,Peter Martin,Farrukh T. Awan,Deborah M. Stephens,Paolo Ghia,Jacqueline C. Barrientos,John M. Pagel,Jennifer A. Woyach,Kathleen A. Burke,Todd Covey,Michael Gulrajani,Ahmed Hamdy,Raquel Izumi,Melanie M. Frigault,Priti Patel,Wayne Rothbaum,Min Hui Wang,Susan O'Brien,Richard R. Furman +24 more
TL;DR: This updated and expanded study confirms the efficacy, durability of response, and long-term safety of acalabrutinib, justifying its further investigation in previously untreated and treated patients with CLL/SLL.
Journal ArticleDOI
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study
John C. Byrd,William G. Wierda,Anna Schuh,Stephen Devereux,Jorge M. Chaves,Jennifer R. Brown,Peter Hillmen,Peter Martin,Farrukh T. Awan,Deborah M. Stephens,Paolo Ghia,Jacqueline C. Barrientos,John M. Pagel,Jennifer A. Woyach,Prista Charuworn,Ahmed Hamdy,Raquel Izumi,Priti Patel,Wayne Rothbaum,Min Hui Wang,Richard R. Furman +20 more
TL;DR: An updated analysis of safety and efficacy in acalabrutinib in patients with relapsed/refractory CLL/small lymphocytic lymphoma (SLL), including those with high-risk disease, in the ongoing Phase 1/2 ACE-CL-001 study is presented.
Journal ArticleDOI
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.
Funda Meric-Bernstam,Muralidhar Beeram,Erika Hamilton,Do Youn Oh,Diana L. Hanna,Yoon-Koo Kang,Elena Elimova,Jorge M. Chaves,Rachel Anne Goodwin,Jeeyun Lee,Lisle Nabell,Sun Young Rha,Jose I. Mayordomo,Anthony B. El-Khoueiry,Shubham Pant,Kanwal Pratap Singh Raghav,Jin Won Kim,Amita Patnaik,T. Gray,Rupert Davies,Mark A. Ozog,Joseph Woolery,Keun Wook Lee +22 more
TL;DR: Zanidatamab is a humanised, bispecific monoclonal antibody directed against two non-overlapping domains of HER2, which has been shown to be an actionable target in various cancer histologies, including biliary tract cancer and colorectal cancer as discussed by the authors .
Journal ArticleDOI
Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study
Philippe L. Bedard,Seock-Ah Im,Elena Elimova,Sun Young Rha,Rachel Anne Goodwin,Cristiano Ferrario,Keun Wook Lee,Diana L. Hanna,Funda Meric-Bernstam,Jose I. Mayordomo,Muralidhar Beeram,Erika Hamilton,Jorge M. Chaves,Melody A. Cobleigh,T. Mwatha,Joseph Woolery,Do Youn Oh +16 more
TL;DR: This phase 1 study evaluated the safety and antitumor activity of zani in combination with chemo in HER2-positive BC pts, finding that zani treatment could be continued if chemo was discontinued due to toxicity, and concluded that stable disease and stable disease control rates were satisfactory.